Millennium Management
SMMT icon

Millennium Management’s Summit Therapeutics SMMT Stock Holding History

Millennium Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,000
Closed -$638K – 6432
2025
Q2 		$638K Sell
30,000
-180,000
-86% -$4.1M ﹤0.01% 4728
2025
Q1 		$4.05M Buy
+210,000
New +$4.21M ﹤0.01% 3070

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management's SMMT Position: Q1 2026 in Review

Millennium Management reduced its Summit Therapeutics (SMMT) stake by 73% in Q1 2026, selling an estimated $5.54M and leaving 126,273 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3702.

Millennium Management first reported a position in SMMT in Q4 2016 and has held it in 21 quarters since. The position peaked at $36.6M in Q4 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Millennium Management held 126,273 shares of Summit Therapeutics worth $2.39M as of Q1 2026.
  • Millennium Management sold 342,744 Summit Therapeutics shares in Q1 2026, an estimated $5.54M.
  • Summit Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3702 holding.
  • Millennium Management first reported a position in Summit Therapeutics in Q4 2016 and has held it in 21 quarters since.
  • Millennium Management's Summit Therapeutics position peaked at $36.6M in Q4 2024.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.